Silk Road Medical Announces Preliminary Third Quarter 2023 Revenue and Provides Revised 2023 Outlook
10 Outubro 2023 - 5:20PM
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on
reducing the risk of stroke and its devastating impact, today
announced preliminary revenue for the quarter ended September 30,
2023, and provided an update to full year 2023 revenue guidance.
Preliminary Third Quarter 2023 Revenue
Preliminary, unaudited third quarter 2023 revenue is expected to
be approximately $44.4 million, an increase of 19% as compared to
the prior year period.
2023 Financial Guidance
Silk Road Medical now projects revenue for the full year 2023 to
range from $170 million to $174 million, which represents 23% to
26% growth over the Company’s prior year revenue.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device
company located in Sunnyvale, California, and Plymouth, Minnesota,
that is focused on reducing the risk of stroke and its devastating
impact. The company has pioneered a new approach for the treatment
of carotid artery disease called TransCarotid Artery
Revascularization (TCAR). TCAR is a clinically proven procedure
combining surgical principles of neuroprotection with minimally
invasive endovascular techniques to treat blockages in the carotid
artery at risk of causing a stroke. For more information on how
Silk Road Medical is delivering brighter patient outcomes through
brighter clinical thinking, visit www.silkroadmed.com and connect
on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
Statements contained in this release that relate to future, not
past, events are forward-looking statements under the Private
Securities Litigation Reform Act of 1995, including Silk Road
Medical’s preliminary, unaudited revenue for third quarter of 2023
and projected full year 2023 revenue guidance. Forward-looking
statements are based on current expectations of future events and
often can be identified by words such as “expect,” “should,”
“project,” “anticipate,” “intend,” “will,” “can,” “may,” “believe,”
“could,” “continue,” “outlook,” “guidance,” “future,” other words
of similar meaning or the use of future dates. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Risks and uncertainties may cause Silk Road
Medical’s actual results to be materially different than those
expressed in or implied by Silk Road Medical’s forward-looking
statements. For Silk Road Medical, such risks and uncertainties
include, among others, a risk that Silk Road Medical’s final third
quarter 2023 revenue results will deviate from the preliminary,
unaudited revenue results in this release; failure to achieve
anticipated revenue and other financial results for full year 2023;
future operating results and financial performance; the ability to
obtain an adequate supply of materials and components from its
third-party suppliers; product development plans and the ability to
commercialize new products in a timely manner; plans to conduct
further clinical trials; the ability to obtain additional
indications or new regulatory approvals or clearances for its
products; use of its products by physicians; the ability to grow
its commercialization infrastructure; the effect of economic
conditions and COVID-19 or similar pandemics on its business;
government and third-party payer coverage and reimbursement;
success in retaining and recruiting key personnel; and the ability
to obtain and maintain intellectual property protection for its
products. More detailed information on these and other factors that
could affect Silk Road Medical’s actual results are described in
its filings with the U.S. Securities and Exchange Commission,
including its most recent quarterly report on Form 10-Q filed with
the Securities and Exchange Commission on August 8, 2023. Silk Road
Medical undertakes no obligation to update its forward-looking
statements.
Investor Contact:Marissa BychGilmartin Group
LLCinvestors@silkroadmed.com
Media:Michael FanucchiSilk Road
Medicalmfanucchi@silkroadmed.com
Silk Road Medical (NASDAQ:SILK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Silk Road Medical (NASDAQ:SILK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024